Why Did The Vanguard Group Inc. Increased Its Shares To Almost $6 Million In BPMX

silver-background-3 (14) (2)

Why Did The Vanguard Group Inc. Increased Its Shares To Almost $6 Million In BPMX – CWEB.com

Institutional investors currently hold major shares in BioPharmX Corporation(BPMX) stock. Majority of the recent share have been purchased by Vanguard Investment firm on 5-13-2018

BioPharmX Corporation (BPMX) stock was most active stock of Wall Street Market on Tuesday. BPMX moved -1.77% to 0.19. BPMX received interesting focus from Active Investors and it has been trading on front line as seeing to it recent volume.

Statistic show the size of the acne treatment market worldwide in 2016 and a forecast for 2025, in billion U.S. dollars. In 2016, the global acne treatment market was worth some 4.9 billion dollars and was expected to grow to over 7 billion by the end of 2025.

Statistic also show the market value of skincare products in Great Britain from 2009 to 2016. The total value of the skincare market in December 2016 was measured at approximately 2.16 billion British pounds

Owner NameDateShared HeldChange (Shares)Change (%)Value (in 1,000s)
VIVO CAPITAL, LLC05/13/201816,128,5152,328,57116.873,306
FRANKLIN RESOURCES INC05/13/20189,749,61500.001,999
VANGUARD GROUP INC05/13/20185,498,9183,541,971181.001,127
GEODE CAPITAL MANAGEMENT, LLC03/31/2018671,686347,719107.33138
VIRTU FINANCIAL LLC03/31/2018426,837426,837New88
BARCLAYS PLC03/31/2018362,900362,900New74
SUSQUEHANNA INTERNATIONAL GROUP, LLP03/31/2018181,335181,335New37
CITADEL ADVISORS LLC03/31/2018146,859146,859New30
MCF ADVISORS LLC03/31/2018105,629105,629New22
JANE STREET GROUP, LLC03/31/201896,94196,941New20
TWO SIGMA SECURITIES, LLC03/31/201893,39047,105101.7719
NORTHERN TRUST CORP03/31/201892,51800.0019
UBS GROUP AG03/31/201870,36736,614108.4814
LADENBURG THALMANN FINANCIAL SERVICES INC.03/31/201864,20000.0013
CREDIT SUISSE AG/03/31/201850,00050,000New10
HOLDERSSHARES
Increased Positions177,708,826
Held Positions715,447,095
Total Institutional Shares2733,878,519

On April 26th, 2018, BioPharmX reports its results for the quarter and year ended January 31st, 2018. For Q4 FY18, total operating expenses were $3.6 million, and net loss was $3.8 million.

For FY18, total operating expenses were $16.7 million, and net loss was $16.6 million. As of January 31st, 2018, cash and cash equivalents were $7.6 million.

BioPharmX Corporation (BPMX) has been working on the following pipeline for new products and FDA approvals.

HYDROPHILIC TOPICAL SYSTEM

1 Patent Issued, 21 Pending

STABILIZES

  • Hydrophilic: non-occlusive, non-oily
  • Non-lipophilic (oil-based)
  • Suitable for APIs degraded in water

FULLY SOLUBILIZES

  • Improves bioavailability
  • Not a suspension
  • Miscible w/ sebum

Higher penetration and targeted delivery

THERAPEUTICS

BPX-01-Acne

BPX-04-Rosacea

BPX-Retinoids

BPX-Combinations

INJECTABLE SYSTEM

1 Patent Pending

CROSSLINKED

  • Proprietary cross-linked injectable delivery system

SUSTAINED RELEASE

  • Prolonged release of biologics and small to mid-sized molecules

Suitable for aesthetics

AESTHETICS

BPX-02

ENCAPSULATION SYSTEM

3 Patents Issued, 4 Pending

ISOLATES

  • Separates hydrophilic APIs from boundary layer

ENCAPSULATES

  • Encapsulates between the hydrophilic and hydrophobic phases of emulsion

Emulsion feels smooth to the touch

COSMETICS

IODINE SYSTEM

1 Patent Allowed, 3 Pending

STABILIZES

  • Oral delivery of iodide and iodate
  • Patented formulation stabilizes iodine

TARGETS

  • Delivery to targeted mammary cells
  • Apoptotic and anti-proliferative effects

Commercially available product since 2014

WOMEN’S HEALTH

BPX-03

Women’s Health Asset for Strategic Partnerships

The patent (U.S. Patent No. 9,918,998), entitled “Pharmaceutical Tetracycline Composition For Dermatological Use,” covers a topical composition comprised of minocycline or another tetracycline-class drug and a method for making such compositions. The patent also covers treatments of dermatological inflammation or infection using a minocycline composition. Current formulations protected by the patent include BPX-01 for the treatment of acne and BPX-04 for the treatment of rosacea.

This is the fourth U.S. patent issuance BioPharmX (BPMX) has received. Three earlier-issued U.S. patents protect the company’s encapsulation delivery system, which can isolate the API. The most recent of these patents, U.S. Patent No. 9,901,586, entitled “Dosage Form Comprising an Active Ingredient and a Plurality of Solid Porous Microcarriers,” was granted Feb. 27.

The US 9,918,998 patent protects tetracycline-class products carried by BioPharmX’s innovative delivery system, which for the first time stabilizes and fully solubilizes these drugs to make them effective in a topical formulation. This includes products that use other tetracycline-class drugs as well as combination products that combine antibiotics with other drugs, for example retinoids.

“This patent protection is a significant milestone for BioPharmX,” said President and Co-founder Anja Krammer. “It recognizes that our development of a topical tetracycline-class drug, something that has eluded the pharmaceutical industry since minocycline was first commercially used in the 1970s, is truly unique.”

BioPharmX has successfully completed a phase 2b trial for BPX-01 for acne and is in phase 3 readiness. The company has reported positive interim results from a feasibility study for BPX-04 for rosacea and is preparing for a phase 2 trial.

Anthony Vendetti from Maxim Group maintained a Buy rating on BioPharmX Corp (NYSE: BPMX), with a price target of $1.50.

The Industry Biotechnology & Medical Research also suggest that  BioPharmX Corporation (BPMX) is currently the cheapest stock against major companies below:

PTIEPain Therapeutics Inc Com New4/23/1810.1530.46%
SNMXSenomyx Inc Com5/14/181.428.40%
VRTXVertex Pharmaceuticals Inc Com5/13/18157.240.81%
ARQLArqule Inc Com5/18/183.390.00%
ICLRIcon Plc Shs5/21/18125.740.00%

Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bullish. Technical indicators also suggest that BioPharmX Corporation (BPMX) , is undervalued.  

CWEB Analysts have Reiterate a Buy Rating for BioPharmX Corporation (BPMX)  and a Price Target of $7 within 12 months.

A possible partnership or major investment for  BioPharmX Corporation (BPMX)  is strongly possible in this coming month by big pharmaceutical company.

Read Full Article and Videos CWEB.com – Trending News, Blog, Shopping

Chart
BPMX data by YCharts

 

[youtube https://www.youtube.com/watch?v=9TXBP1t2rUc&w=560&h=315]

Comments


CWEB.com is not registered as an investment adviser with the U.S. Securities and Exchange Commission. Rather, CWEB.com relies upon the “publisher’s exclusion” from the definition of investment adviser as provided under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws.

Full Disclaimer

%d bloggers like this: